Clinically indicated electrical stimulation strategies to treat patients with medically refractory epilepsy

Ali Izadi, Katelynn Ondek, Amber Schedlbauer, Inna Keselman, Kiarash Shahlaie, Gene G Gurkoff

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Focal epilepsies represent approximately half of all diagnoses, and more than one-third of these patients are refractory to pharmacologic treatment. Although resection can result in seizure freedom, many patients do not meet surgical criteria, as seizures may be multifocal in origin or have a focus in an eloquent region of the brain. For these individuals, several U.S. Food and Drug Administration (FDA)–approved electrical stimulation paradigms serve as alternative options, including vagus nerve stimulation, responsive neurostimulation, and stimulation of the anterior nucleus of the thalamus. All of these are safe, flexible, and lead to progressive seizure control over time when used as an adjunctive therapy to antiepileptic drugs. Focal epilepsies frequently involve significant comorbidities such as cognitive decline. Similar to antiepilepsy medications and surgical resection, current stimulation targets and parameters have yet to address cognitive impairments directly, with patients reporting persistent comorbidities associated with focal epilepsy despite a significant reduction in the number of their seizures. Although low-frequency theta oscillations of the septohippocampal network are critical for modulating cellular activity and, in turn, cognitive processing, the coordination of neural excitability is also imperative for preventing seizures. In this review, we summarize current FDA-approved electrical stimulation paradigms and propose that theta oscillations of the medial septal nucleus represent a novel neuromodulation target for concurrent seizure reduction and cognitive improvement in epilepsy. Ultimately, further advancements in clinical neurostimulation strategies will allow for the efficient treatment of both seizures and comorbidities, thereby improving overall quality of life for patients with epilepsy.

Original languageEnglish (US)
Pages (from-to)198-209
Number of pages12
JournalEpilepsia Open
Volume3
DOIs
StatePublished - Dec 1 2018

Fingerprint

Electric Stimulation
Epilepsy
Seizures
Partial Epilepsy
Comorbidity
United States Food and Drug Administration
Anterior Thalamic Nuclei
Vagus Nerve Stimulation
Septal Nuclei
Anticonvulsants
Therapeutics
Quality of Life
Brain

Keywords

  • Deep brain stimulation
  • Electrical stimulation
  • Epilepsy
  • Medial septal nucleus
  • Theta oscillations

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Clinically indicated electrical stimulation strategies to treat patients with medically refractory epilepsy. / Izadi, Ali; Ondek, Katelynn; Schedlbauer, Amber; Keselman, Inna; Shahlaie, Kiarash; Gurkoff, Gene G.

In: Epilepsia Open, Vol. 3, 01.12.2018, p. 198-209.

Research output: Contribution to journalArticle

@article{e80d4c971f0748189cae00bf383ed5ad,
title = "Clinically indicated electrical stimulation strategies to treat patients with medically refractory epilepsy",
abstract = "Focal epilepsies represent approximately half of all diagnoses, and more than one-third of these patients are refractory to pharmacologic treatment. Although resection can result in seizure freedom, many patients do not meet surgical criteria, as seizures may be multifocal in origin or have a focus in an eloquent region of the brain. For these individuals, several U.S. Food and Drug Administration (FDA)–approved electrical stimulation paradigms serve as alternative options, including vagus nerve stimulation, responsive neurostimulation, and stimulation of the anterior nucleus of the thalamus. All of these are safe, flexible, and lead to progressive seizure control over time when used as an adjunctive therapy to antiepileptic drugs. Focal epilepsies frequently involve significant comorbidities such as cognitive decline. Similar to antiepilepsy medications and surgical resection, current stimulation targets and parameters have yet to address cognitive impairments directly, with patients reporting persistent comorbidities associated with focal epilepsy despite a significant reduction in the number of their seizures. Although low-frequency theta oscillations of the septohippocampal network are critical for modulating cellular activity and, in turn, cognitive processing, the coordination of neural excitability is also imperative for preventing seizures. In this review, we summarize current FDA-approved electrical stimulation paradigms and propose that theta oscillations of the medial septal nucleus represent a novel neuromodulation target for concurrent seizure reduction and cognitive improvement in epilepsy. Ultimately, further advancements in clinical neurostimulation strategies will allow for the efficient treatment of both seizures and comorbidities, thereby improving overall quality of life for patients with epilepsy.",
keywords = "Deep brain stimulation, Electrical stimulation, Epilepsy, Medial septal nucleus, Theta oscillations",
author = "Ali Izadi and Katelynn Ondek and Amber Schedlbauer and Inna Keselman and Kiarash Shahlaie and Gurkoff, {Gene G}",
year = "2018",
month = "12",
day = "1",
doi = "10.1002/epi4.12276",
language = "English (US)",
volume = "3",
pages = "198--209",
journal = "Epilepsia Open",
issn = "2470-9239",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Clinically indicated electrical stimulation strategies to treat patients with medically refractory epilepsy

AU - Izadi, Ali

AU - Ondek, Katelynn

AU - Schedlbauer, Amber

AU - Keselman, Inna

AU - Shahlaie, Kiarash

AU - Gurkoff, Gene G

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Focal epilepsies represent approximately half of all diagnoses, and more than one-third of these patients are refractory to pharmacologic treatment. Although resection can result in seizure freedom, many patients do not meet surgical criteria, as seizures may be multifocal in origin or have a focus in an eloquent region of the brain. For these individuals, several U.S. Food and Drug Administration (FDA)–approved electrical stimulation paradigms serve as alternative options, including vagus nerve stimulation, responsive neurostimulation, and stimulation of the anterior nucleus of the thalamus. All of these are safe, flexible, and lead to progressive seizure control over time when used as an adjunctive therapy to antiepileptic drugs. Focal epilepsies frequently involve significant comorbidities such as cognitive decline. Similar to antiepilepsy medications and surgical resection, current stimulation targets and parameters have yet to address cognitive impairments directly, with patients reporting persistent comorbidities associated with focal epilepsy despite a significant reduction in the number of their seizures. Although low-frequency theta oscillations of the septohippocampal network are critical for modulating cellular activity and, in turn, cognitive processing, the coordination of neural excitability is also imperative for preventing seizures. In this review, we summarize current FDA-approved electrical stimulation paradigms and propose that theta oscillations of the medial septal nucleus represent a novel neuromodulation target for concurrent seizure reduction and cognitive improvement in epilepsy. Ultimately, further advancements in clinical neurostimulation strategies will allow for the efficient treatment of both seizures and comorbidities, thereby improving overall quality of life for patients with epilepsy.

AB - Focal epilepsies represent approximately half of all diagnoses, and more than one-third of these patients are refractory to pharmacologic treatment. Although resection can result in seizure freedom, many patients do not meet surgical criteria, as seizures may be multifocal in origin or have a focus in an eloquent region of the brain. For these individuals, several U.S. Food and Drug Administration (FDA)–approved electrical stimulation paradigms serve as alternative options, including vagus nerve stimulation, responsive neurostimulation, and stimulation of the anterior nucleus of the thalamus. All of these are safe, flexible, and lead to progressive seizure control over time when used as an adjunctive therapy to antiepileptic drugs. Focal epilepsies frequently involve significant comorbidities such as cognitive decline. Similar to antiepilepsy medications and surgical resection, current stimulation targets and parameters have yet to address cognitive impairments directly, with patients reporting persistent comorbidities associated with focal epilepsy despite a significant reduction in the number of their seizures. Although low-frequency theta oscillations of the septohippocampal network are critical for modulating cellular activity and, in turn, cognitive processing, the coordination of neural excitability is also imperative for preventing seizures. In this review, we summarize current FDA-approved electrical stimulation paradigms and propose that theta oscillations of the medial septal nucleus represent a novel neuromodulation target for concurrent seizure reduction and cognitive improvement in epilepsy. Ultimately, further advancements in clinical neurostimulation strategies will allow for the efficient treatment of both seizures and comorbidities, thereby improving overall quality of life for patients with epilepsy.

KW - Deep brain stimulation

KW - Electrical stimulation

KW - Epilepsy

KW - Medial septal nucleus

KW - Theta oscillations

UR - http://www.scopus.com/inward/record.url?scp=85061827283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061827283&partnerID=8YFLogxK

U2 - 10.1002/epi4.12276

DO - 10.1002/epi4.12276

M3 - Article

AN - SCOPUS:85061827283

VL - 3

SP - 198

EP - 209

JO - Epilepsia Open

JF - Epilepsia Open

SN - 2470-9239

ER -